8-K Announcements
6Material company update
Mar 9, 2026·SEC
Material company update
Feb 17, 2026·SEC
Material company update
Feb 4, 2026·SEC
Coherus Oncology, Inc.(CHRS)Earnings, Financials & Key Ratios
CHRS•NASDAQ
$1.75
$212M mkt cap·1.2× P/E·Price updated May 6, 2026
AboutCoherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, Anti-ILT4 monoclonal antibody for solid tumors. In addition, the company offers GSK4381562, an antibody targeting CD112R to treat tumor cells; YUSIMRY, a biosimilar to Humira for inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis; and CIMERLI, a Lucentis biosimilar to treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.Show more
- Revenue$42M-84.2%
- EBITDA-$184M-73.2%
- Net Income$168M+489.4%
- EPS (Diluted)1.43+472.0%
- Gross Margin-37.31%-166.7%
- EBITDA Margin-436.88%-996.2%
- Operating Margin-429.51%-926.8%
- Net Margin398.43%+3631.1%
- ROE275.39%
- Debt/Equity0.02
CHRS Key Insights
Coherus Oncology, Inc. (CHRS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Excellent 3Y average ROE of 275.4%
- ✓Healthy 5Y average net margin of 18.1%
✗Weaknesses
- ✗Negative free cash flow
- ✗Sales declining 38.4% over 5 years
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
CHRS Price & Volume
Coherus Oncology, Inc. (CHRS) stock price & volume — 10-year historical chart
Loading chart...
CHRS Growth Metrics
Coherus Oncology, Inc. (CHRS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years3.45%
5 Years-38.41%
3 Years-41.54%
TTM-78.06%
Profit CAGR
10 Years-
5 Years4.91%
3 Years-
TTM489.41%
EPS CAGR
10 Years-
5 Years-2.46%
3 Years-
TTM-943.24%
Return on Capital
10 Years-73.83%
5 Years-68.62%
3 Years-79.83%
Last Year-127.78%
CHRS Recent Earnings
Coherus Oncology, Inc. (CHRS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 2/12 qtrs (17%)
Q2 2026Latest
Mar 9, 2026EPS
$0.34
Est $0.36
+4.2%
Revenue
$13M
Est $14M
-8.4%
Q4 2025
Nov 6, 2025EPS
$0.33
Est $0.32
-3.1%
Revenue
$12M
Est $14M
-17.9%
Q3 2025
Aug 7, 2025EPS
$0.34
Est $0.31
-9.7%
Revenue
$10M
Est $12M
-14.5%
Q2 2025
May 12, 2025EPS
$0.35
Est $0.31
-12.9%
Revenue
$8M
Est $61M
-87.5%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 9, 2026 | $0.34vs $0.36+4.2% | $13Mvs $14M-8.4% |
| Q4 2025 | Nov 6, 2025 | $0.33vs $0.32-3.1% | $12Mvs $14M-17.9% |
| Q3 2025 | Aug 7, 2025 | $0.34vs $0.31-9.7% | $10Mvs $12M-14.5% |
| Q2 2025 | May 12, 2025 | $0.35vs $0.31-12.9% | $8Mvs $61M-87.5% |
Based on last 12 quarters of dataView full earnings history →
CHRS Peer Comparison
Coherus Oncology, Inc. (CHRS) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PRGO | 1.69B | 12.26 | -1.19 | -2.75% | -43.5% | -50.65% | 1.35 | |
 AMRX | 4.28B | 13.62 | 61.91 | 8.05% | 2.39% | 7.47% | 0.13 | |
 HCM | 2.31B | 13.43 | 61.05 | -24.8% | 77.53% | 46.37% | 0.12 | |
 TGTX | 6.7B | 41.97 | 15.15 | 87.32% | 65.95% | 87.36% | 0.40 | |
 MGNX | 190.59M | 3.01 | -2.55 | 0.78% | -49.91% | -120.2% | 0.66 | |
 VTRS | 18.37B | 15.95 | -5.32 | -2.98% | -24.58% | -23.89% | 0.98 | |
 PFGC | 14.59B | 92.88 | 42.61 | 8.61% | 0.49% | 7.13% | 1.79 | |
 SGMT | 271.06M | 8.38 | -5.30 | -40.85% | 0.00 |
Compare CHRS vs Peers
Coherus Oncology, Inc. (CHRS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CHRS Income Statement
Coherus Oncology, Inc. (CHRS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 1.56M | 1.56M | 356.07M | 475.82M | 326.55M | 211.04M | 257.24M | 266.96M | 42.17M |
| Revenue Growth % | -99.18% | 0% | 22783.74% | 33.63% | -31.37% | -35.37% | 21.89% | 3.78% | -84.2% |
| Cost of Goods Sold | 160.53M | 3.23M | 17.08M | 37.67M | 57.59M | 70.08M | 158.99M | 117.55M | 9.72M |
| COGS % of Revenue | 10316.9% | 207.9% | 4.8% | 7.92% | 17.64% | 33.21% | 61.81% | 44.03% | 23.04% |
| Gross Profit | -158.97M▲ 0% | -1.68M▲ 98.9% | 338.99M▲ 20290.2% | 438.16M▲ 29.3% | 268.96M▼ 38.6% | 140.96M▼ 47.6% | 98.25M▼ 30.3% | 149.41M▲ 52.1% | -15.73M▼ 110.5% |
| Gross Margin % | -10216.9% | -107.9% | 95.2% | 92.08% | 82.36% | 66.79% | 38.19% | 55.97% | -37.31% |
| Gross Profit Growth % | -147.11% | 98.94% | 20290.17% | 29.25% | -38.62% | -47.59% | -30.3% | 52.07% | -110.53% |
| Operating Expenses | 233.69M | 204.42M | 231.22M | 281.84M | 532.82M | 397.84M | 301.45M | 261.07M | 216.93M |
| OpEx % of Revenue | 15018.77% | 13137.28% | 64.94% | 59.23% | 163.17% | 188.51% | 117.18% | 97.8% | 514.4% |
| Selling, General & Admin | 71.3M | 94.18M | 137.04M | 139.08M | 169.71M | 198.48M | 185.62M | 150.44M | 100.6M |
| SG&A % of Revenue | 4582.45% | 6052.51% | 38.49% | 29.23% | 51.97% | 94.05% | 72.16% | 56.35% | 238.56% |
| Research & Development | 162.39M | 110.24M | 94.19M | 142.76M | 363.11M | 199.36M | 109.44M | 93.34M | 108.89M |
| R&D % of Revenue | 10436.31% | 7084.77% | 26.45% | 30% | 111.19% | 94.46% | 42.54% | 34.96% | 258.2% |
| Other Operating Expenses | 3.4M | 4.69M | 0 | 0 | 0 | 0 | 6.4M | 17.3M | 7.44M |
| Operating Income | -232.14M▲ 0% | -204.42M▲ 11.9% | 107.77M▲ 152.7% | 156.32M▲ 45.1% | -263.86M▼ 268.8% | -256.88M▲ 2.6% | -203.2M▲ 20.9% | -111.67M▲ 45.0% | -181.13M▼ 62.2% |
| Operating Margin % | -14918.77% | -13137.28% | 30.27% | 32.85% | -80.8% | -121.72% | -78.99% | -41.83% | -429.51% |
| Operating Income Growth % | -100.24% | 11.94% | 152.72% | 45.05% | -268.79% | 2.64% | 20.9% | 45.05% | -62.21% |
| EBITDA | -228.74M | -201.18M | 111.03M | 161.29M | -260.4M | -253.18M | -199.41M | -106.39M | -184.24M |
| EBITDA Margin % | -14700.39% | -12929.37% | 31.18% | 33.9% | -79.74% | -119.97% | -77.52% | -39.85% | -436.88% |
| EBITDA Growth % | -102.54% | 12.05% | 155.19% | 45.27% | -261.45% | 2.77% | 21.24% | 46.65% | -73.17% |
| D&A (Non-Cash Add-back) | 3.4M | 3.23M | 3.26M | 4.97M | 3.45M | 3.7M | 3.79M | 5.28M | -3.11M |
| EBIT | -228.73M | -200.56M | 107.77M | 156.87M | -264.14M | -259.28M | -197.73M | 55.66M | 0 |
| Net Interest Income | -9.55M | 0 | -17.6M | -21.17M | -22.96M | -32.47M | -40.54M | -27.16M | 0 |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 9.55M | 9.68M | 17.6M | 21.17M | 22.96M | 32.47M | 40.54M | 27.16M | -22.16M |
| Other Income/Expense | -6.15M | -4.99M | -14.99M | -20.61M | -23.24M | -34.87M | -35.07M | 140.17M | -1.99M |
| Pretax Income | -238.29M▲ 0% | -209.41M▲ 12.1% | 92.78M▲ 144.3% | 135.71M▲ 46.3% | -287.1M▼ 311.6% | -291.75M▼ 1.6% | -238.27M▲ 18.3% | 28.51M▲ 112.0% | -183.12M▼ 742.4% |
| Pretax Margin % | -15314.01% | -13458.16% | 26.06% | 28.52% | -87.92% | -138.24% | -92.62% | 10.68% | -434.23% |
| Income Tax | 0 | 0 | 2.94M | 3.46M | 0 | 0 | -380K | 0 | -332.81M |
| Effective Tax Rate % | 0% | 0% | 3.17% | 2.55% | 0% | 0% | 0.16% | 0% | 181.74% |
| Net Income | -238.17M▲ 0% | -209.34M▲ 12.1% | 89.83M▲ 142.9% | 132.24M▲ 47.2% | -287.1M▼ 317.1% | -291.75M▼ 1.6% | -237.89M▲ 18.5% | 28.51M▲ 112.0% | 168.02M▲ 489.4% |
| Net Margin % | -15306.56% | -13453.66% | 25.23% | 27.79% | -87.92% | -138.24% | -92.48% | 10.68% | 398.43% |
| Net Income Growth % | -87.04% | 12.11% | 142.91% | 47.21% | -317.1% | -1.62% | 18.46% | 111.98% | 489.41% |
| Net Income (Continuing) | -238.29M | -209.41M | 89.83M | 132.24M | -287.1M | -291.75M | -237.89M | 28.51M | 94.8M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 18.34M |
| Minority Interest | -1.29M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -4.48▲ 0% | -3.22▲ 28.1% | 1.23▲ 138.2% | 1.62▲ 31.7% | -3.81▼ 335.2% | -3.76▲ 1.3% | -2.53▲ 32.7% | 0.25▲ 109.9% | 1.43▲ 472.0% |
| EPS Growth % | -47.37% | 28.13% | 138.2% | 31.71% | -335.19% | 1.31% | 32.71% | 109.88% | 472% |
| EPS (Basic) | -4.48 | -3.22 | 1.29 | 1.85 | -3.81 | -3.76 | -2.53 | 0.25 | 1.43 |
| Diluted Shares Outstanding | 53.13M | 65.03M | 73.19M | 83.49M | 75.45M | 77.63M | 94.16M | 114.83M | 120.37M |
| Basic Shares Outstanding | 53.13M | 65.01M | 69.68M | 71.41M | 75.45M | 77.63M | 94.16M | 114.55M | 120.37M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
CHRS Balance Sheet
Coherus Oncology, Inc. (CHRS) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 126.91M | 72.36M | 343.01M | 767.48M | 602.32M | 381.23M | 475.63M | 341.58M | 193.11M |
| Cash & Short-Term Investments | 126.91M | 72.36M | 177.67M | 541.16M | 417.19M | 191.68M | 117.75M | 125.99M | 172.13M |
| Cash Only | 126.91M | 72.36M | 177.67M | 541.16M | 417.19M | 63.55M | 102.89M | 125.99M | 88.88M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 128.13M | 14.86M | 0 | 83.25M |
| Accounts Receivable | 0 | 0 | 141.99M | 157.05M | 123.02M | 109.96M | 260.52M | 122.33M | 17.82M |
| Days Sales Outstanding | - | - | 145.55 | 120.47 | 137.51 | 190.18 | 369.65 | 167.26 | 154.19 |
| Inventory | 0 | 1.66M | 9.81M | 44.23M | 37.64M | 38.79M | 62.6M | 70.09M | 3.17M |
| Days Inventory Outstanding | - | 187.18 | 209.6 | 428.63 | 238.57 | 202.03 | 143.72 | 217.64 | 119.15 |
| Other Current Assets | 202K | 50K | 0 | 0 | 10.8M | 22.92M | 11.1M | 11.53M | 0 |
| Total Non-Current Assets | 35.7M | 27.11M | 65.92M | 74.17M | 77.01M | 99.61M | 153.97M | 106.95M | 46.24M |
| Property, Plant & Equipment | 12.77M | 6.66M | 16.49M | 10.11M | 7.81M | 8.75M | 5.12M | 2.84M | 0 |
| Fixed Asset Turnover | 0.12x | 0.23x | 21.59x | 47.07x | 41.80x | 24.11x | 50.25x | 94.10x | - |
| Goodwill | 943K | 943K | 943K | 943K | 943K | 943K | 943K | 0 | 0 |
| Intangible Assets | 2.62M | 2.62M | 2.62M | 2.62M | 2.62M | 4.99M | 70.73M | 53.65M | 46.24M |
| Long-Term Investments | 785K | 785K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 19.36M | 16.89M | 45.87M | 60.5M | 65.64M | 84.93M | 77.18M | 50.47M | 0 |
| Total Assets | 162.61M▲ 0% | 99.47M▼ 38.8% | 408.93M▲ 311.1% | 841.65M▲ 105.8% | 679.33M▼ 19.3% | 480.85M▼ 29.2% | 629.6M▲ 30.9% | 448.53M▼ 28.8% | 258.34M▼ 42.4% |
| Asset Turnover | 0.01x | 0.02x | 0.87x | 0.57x | 0.48x | 0.44x | 0.41x | 0.60x | 0.16x |
| Asset Growth % | -8.89% | -38.83% | 311.12% | 105.82% | -19.29% | -29.22% | 30.94% | -28.76% | -42.4% |
| Total Current Liabilities | 28.39M | 33.26M | 114.97M | 145.65M | 165.33M | 138.69M | 331.77M | 282.98M | 140.39M |
| Accounts Payable | 15.71M | 15.29M | 25.98M | 15.2M | 16.16M | 11.53M | 35.22M | 28.46M | 0 |
| Days Payables Outstanding | 35.73 | 1.73K | 555.37 | 147.3 | 102.41 | 60.03 | 80.85 | 88.36 | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 8.82M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 3.63M | 419K | 20.61M | 22.24M | 22.01M | 22.61M | 21.52M | 33.11M | 140.39M |
| Current Ratio | 4.47x | 2.18x | 2.98x | 5.27x | 3.64x | 2.75x | 1.43x | 1.21x | 1.38x |
| Quick Ratio | 4.47x | 2.13x | 2.90x | 4.97x | 3.42x | 2.47x | 1.24x | 0.96x | 1.35x |
| Cash Conversion Cycle | - | - | -200.21 | 401.79 | 273.66 | 332.18 | 432.52 | 296.55 | - |
| Total Non-Current Liabilities | 132.08M | 138.06M | 188.74M | 415.02M | 416.28M | 479.57M | 491.26M | 297.54M | 56.94M |
| Long-Term Debt | 101.61M | 103.09M | 178.39M | 404.02M | 408.28M | 471.06M | 473.37M | 264.93M | 1.46M |
| Capital Lease Obligations | 0 | 0 | 10.26M | 9.95M | 7.25M | 5.05M | 5.33M | 3.29M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 1.1M | 1.1M | 0 |
| Other Non-Current Liabilities | 2.07M | 1.71M | 102K | 1.05M | 750K | 3.47M | 11.46M | 28.23M | 55.49M |
| Total Liabilities | 132.08M | 138.06M | 303.71M | 560.67M | 581.61M | 618.26M | 823.03M | 580.52M | 197.33M |
| Total Debt | 101.41M | 103.09M | 188.64M | 417.1M | 419.02M | 480.42M | 480.84M | 269.9M | 1.46M |
| Net Debt | -25.5M | 30.74M | 10.97M | -124.06M | 1.83M | 416.88M | 377.95M | 143.92M | -87.42M |
| Debt / Equity | 3.47x | - | 1.79x | 1.48x | 4.29x | - | - | - | 0.02x |
| Debt / EBITDA | - | - | 1.70x | 2.59x | - | - | - | - | - |
| Net Debt / EBITDA | - | - | 0.10x | -0.77x | - | - | - | - | - |
| Interest Coverage | -24.30x | -21.11x | 6.12x | 7.39x | -11.49x | -7.91x | -5.01x | -4.11x | - |
| Total Equity | 29.25M▲ 0% | -38.59M▼ 232.0% | 105.21M▲ 372.6% | 280.97M▲ 167.1% | 97.73M▼ 65.2% | -137.42M▼ 240.6% | -193.43M▼ 40.8% | -131.99M▲ 31.8% | 61.01M▲ 146.2% |
| Equity Growth % | 60.86% | -231.95% | 372.64% | 167.05% | -65.22% | -240.62% | -40.76% | 31.76% | 146.23% |
| Book Value per Share | 0.55 | -0.59 | 1.44 | 3.37 | 1.30 | -1.77 | -2.05 | -1.15 | 0.51 |
| Total Shareholders' Equity | 30.54M | -38.59M | 105.21M | 280.97M | 97.73M | -137.42M | -193.43M | -131.99M | 61.01M |
| Common Stock | 6K | 7K | 7K | 7K | 7K | 8K | 11K | 12K | 12K |
| Retained Earnings | -775.49M | -984.83M | -895M | -762.75M | -1.05B | -1.34B | -1.58B | -1.55B | -1.38B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -750K | -282K | -558K | -270K | -270K | -249K | -248K | -275K | -195K |
| Minority Interest | -1.29M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CHRS Cash Flow Statement
Coherus Oncology, Inc. (CHRS) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -200.29M | -159.27M | 28.36M | 154.15M | -37.43M | -241.12M | -174.88M | -20.44M | -138.51M |
| Operating CF Margin % | -12871.85% | -10235.6% | 7.96% | 32.4% | -11.46% | -114.25% | -67.98% | -7.66% | -328.45% |
| Operating CF Growth % | 20.69% | 20.48% | 117.8% | 443.63% | -124.28% | -544.17% | 27.47% | 88.31% | -577.66% |
| Net Income | -238.29M | -209.41M | 89.83M | 132.24M | -287.1M | -291.75M | -237.89M | 28.51M | 168.02M |
| Depreciation & Amortization | 3.4M | 3.23M | 3.26M | 2.89M | 3.45M | 3.7M | 3.79M | 5.28M | 0 |
| Stock-Based Compensation | 36.06M | 34.8M | 33.59M | 38.16M | 51.36M | 50.74M | 43.11M | 27.8M | 0 |
| Deferred Taxes | 453K | 3.56M | -55K | 0 | 9.44M | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 3.22M | -1.75M | 15.65M | 15.5M | 143.05M | 75.45M | 52.93M | -137.92M | -306.54M |
| Working Capital Changes | -5.13M | 10.3M | -113.93M | -34.65M | 42.36M | -79.26M | -36.83M | 55.89M | 0 |
| Change in Receivables | 1.86M | 8.28M | -141.99M | -15.22M | 34.06M | 13.05M | -150.68M | 149.35M | 0 |
| Change in Inventory | -148K | -5.48M | -48.18M | -38.36M | -6.25M | -47.35M | -46.73M | -31.95M | 0 |
| Change in Payables | -4.45M | -534K | 9.89M | -9.82M | 874K | -4.55M | 23.76M | -3.94M | 0 |
| Cash from Investing | -4.42M | -1.19M | -12.73M | -14.4M | -138.41M | -166.85M | 144.64M | 230.32M | 375.09M |
| Capital Expenditures | -4.57M | -789K | -12.9M | -7.23M | -1.29M | -2.04M | -286K | 0 | 0 |
| CapEx % of Revenue | 293.89% | 50.71% | 3.62% | 1.52% | 0.39% | 0.97% | 0.11% | - | - |
| Acquisitions | 0 | -700K | 1.66M | 0 | 1.29M | 0 | 845K | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 156K | 301K | -1.66M | -7.33M | -137.29M | -37.43M | 5.95M | 215.43M | 457.46M |
| Cash from Financing | 206.79M | 105.42M | 89.37M | 223.95M | 51.88M | 54.33M | 69.6M | -186.97M | -273.7M |
| Debt Issued (Net) | 0 | 0 | 72.95M | 222.16M | -672K | 49.93M | 0 | -223.41M | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 0 | -1000K | 1000K | 1000K | 1000K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -544K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 482K | 3.67M | 8.26M | 1.79M | 54.3M | -1.96M | -4.62M | 34.98M | -273.7M |
| Net Change in Cash | 1.96M▲ 0% | -54.56M▼ 2878.3% | 104.72M▲ 291.9% | 363.69M▲ 247.3% | -123.96M▼ 134.1% | -353.65M▼ 185.3% | 39.34M▲ 111.1% | 22.91M▼ 41.8% | -37.13M▼ 262.1% |
| Free Cash Flow | -204.86M▲ 0% | -160.06M▲ 21.9% | 15.46M▲ 109.7% | 146.91M▲ 850.4% | -38.72M▼ 126.4% | -243.16M▼ 528.0% | -175.17M▲ 28.0% | -20.44M▲ 88.3% | -138.51M▼ 577.7% |
| FCF Margin % | -13165.75% | -10286.31% | 4.34% | 30.88% | -11.86% | -115.22% | -68.09% | -7.66% | -328.45% |
| FCF Growth % | 20.92% | 21.87% | 109.66% | 850.41% | -126.36% | -527.99% | 27.96% | 88.33% | -577.66% |
| FCF per Share | -3.86 | -2.46 | 0.21 | 1.76 | -0.51 | -3.13 | -1.86 | -0.18 | -1.15 |
| FCF Conversion (FCF/Net Income) | 0.84x | 0.76x | 0.32x | 1.17x | 0.13x | 0.83x | 0.74x | -0.72x | -0.82x |
| Interest Paid | 0 | 0 | 15.26M | 16.96M | 18.68M | 34.88M | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 1.73M | 3.95M | 1.22M | 40K | 0 | 0 | 0 |
CHRS Key Ratios
Coherus Oncology, Inc. (CHRS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -2418.56% | -1004.36% | - | 269.68% | 68.49% | -151.62% | - | - | - | 275.39% |
| Return on Invested Capital (ROIC) | - | - | - | 149.22% | 85.86% | -154.32% | -101.66% | -65.69% | -85.26% | - |
| Gross Margin | -33.84% | -10216.9% | -107.9% | 95.2% | 92.08% | 82.36% | 66.79% | 38.19% | 55.97% | -37.31% |
| Net Margin | -66.98% | -15306.56% | -13453.66% | 25.23% | 27.79% | -87.92% | -138.24% | -92.48% | 10.68% | 398.43% |
| Debt / Equity | 5.51x | 3.47x | - | 1.79x | 1.48x | 4.29x | - | - | - | 0.02x |
| Interest Coverage | -14.53x | -24.30x | -21.11x | 6.12x | 7.39x | -11.49x | -7.91x | -5.01x | -4.11x | - |
| FCF Conversion | 1.98x | 0.84x | 0.76x | 0.32x | 1.17x | 0.13x | 0.83x | 0.74x | -0.72x | -0.82x |
| Revenue Growth | 532.82% | -99.18% | 0% | 22783.74% | 33.63% | -31.37% | -35.37% | 21.89% | 3.78% | -84.2% |
CHRS SEC Filings & Documents
Coherus Oncology, Inc. (CHRS) SEC filings — annual & quarterly reports (10-K, 10-Q)
CHRS Frequently Asked Questions
Coherus Oncology, Inc. (CHRS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Coherus Oncology, Inc. (CHRS) reported $42.2M in revenue for fiscal year 2025. This represents a 2121% increase from $1.9M in 2012.
Coherus Oncology, Inc. (CHRS) saw revenue decline by 84.2% over the past year.
Yes, Coherus Oncology, Inc. (CHRS) is profitable, generating $168.0M in net income for fiscal year 2025 (398.4% net margin).
Dividend & Returns
Coherus Oncology, Inc. (CHRS) has a return on equity (ROE) of 275.4%. This is excellent, indicating efficient use of shareholder capital.
Coherus Oncology, Inc. (CHRS) had negative free cash flow of $138.5M in fiscal year 2025, likely due to heavy capital investments.
Explore More CHRS
Coherus Oncology, Inc. (CHRS) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates